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ABSTRACT Plasmodium vivax causes heavy burdens of disease across malarious re-
gions worldwide. Mature P. vivax asexual and transmissive gametocyte stages occur
in the blood circulation, and it is often assumed that accumulation/sequestration in
tissues is not an important phase in their development. Here, we present a system-
atic study of P. vivax stage distributions in infected tissues of nonhuman primate
(NHP) malaria models as well as in blood from human infections. In a comparative
analysis of the transcriptomes of P. vivax and Plasmodium falciparum blood-stage
parasites, we found a conserved cascade of stage-speciﬁc gene expression despite
the greatly different gametocyte maturity times of these two species. Using this
knowledge, we validated a set of conserved asexual- and gametocyte-stage markers
both by quantitative real-time PCR and by antibody assays of peripheral blood sam-
ples from infected patients and NHP (Aotus sp.). Histological analyses of P. vivax par-
asites in organs of 13 infected NHP (Aotus and Saimiri species) demonstrated a ma-
jor fraction of immature gametocytes in the parenchyma of the bone marrow, while
asexual schizont forms were enriched to a somewhat lesser extent in this region of
the bone marrow as well as in sinusoids of the liver. These ﬁndings suggest that the
bone marrow is an important reservoir for gametocyte development and prolifera-
tion of malaria parasites.
IMPORTANCE Plasmodium vivax malaria continues to cause major public health
burdens worldwide. Yet, signiﬁcant knowledge gaps in the basic biology and epide-
miology of P. vivax malaria remain, largely due to limited available tools for research
and diagnostics. Here, we present a systematic examination of tissue sequestration
during P. vivax infection. Studies of nonhuman primates and malaria patients re-
vealed enrichment of developing sexual stages (gametocytes) and mature replicative
stages (schizonts) in the bone marrow and liver, relative to those present in periph-
eral blood. Identiﬁcation of the bone marrow as a major P. vivax tissue reservoir has
important implications for parasite diagnosis and treatment.
KEYWORDS Aotus, real-time PCR, Saimiri, blood-stage parasites, gametocytes,
immunohistochemistry, laboratory animal models, malaria, transcriptome
Received 3 April 2018 Accepted 11 April
2018 Published 8 May 2018
Citation Obaldia N, III, Meibalan E, Sa JM, Ma S,
Clark MA, Mejia P, Moraes Barros RR, Otero W,
Ferreira MU, Mitchell JR, Milner DA,
Huttenhower C, Wirth DF, Duraisingh MT,
Wellems TE, Marti M. 2018. Bone marrow is a
major parasite reservoir in Plasmodium vivax
infection. mBio 9:e00625-18. https://doi.org/10
.1128/mBio.00625-18.
Editor Jon P. Boyle, University of Pittsburgh
Copyright © 2018 Obaldia et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Matthias Marti,
matthias.marti@glasgow.ac.uk.
N.O. and E.M. are co-ﬁrst authors.
This article is a direct contribution from a
Fellow of the American Academy of
Microbiology. Solicited external reviewers:
Clemens Kocken, Biomedical Primate Research
Centre; Hernando Del Portillo, ISGlobal.
RESEARCH ARTICLE
crossm
May/June 2018 Volume 9 Issue 3 e00625-18 ® mbio.asm.org 1
 
m
bio.asm
.org
 o
n
 M
ay 11, 2018 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
Nearly half of the world’s population lives in areas at risk of malaria transmission (1).In regions outside of sub-Saharan Africa where malaria is endemic, Plasmodium
vivax dominates the public health burden from this infectious disease (2–4). P. vivax is
also increasingly recognized in Africa, where it has been demonstrated to cause
infections of Duffy-negative individuals (5). First-line treatment with chloroquine fre-
quently fails against drug-resistant P. vivax in the Indonesian Archipelago, while the use
of primaquine is dangerous to patients with glucose-6-phosphate dehydrogenase
deﬁciency and can be unreliable against the dormant liver-stage forms (hypnozoites) of
some strains (6, 7). The human burden of P. vivax malaria is gaining greater attention,
notably in areas where it persists after the elimination of P. falciparum by malaria
control programs (8). Yet, research on P. vivax has generally lagged behind research on
P. falciparum (3, 9, 10), while much of our knowledge of P. vivax biology has been
founded on experimental infections of nonhuman primates (NHP) and mosquitoes (11).
Practical methods for continuous in vitro culture of P. vivax remain elusive (12–16), and
genetic modiﬁcation of the parasite has been possible only with the use of NHP models
(17). Malaria control and elimination agendas have highlighted the need for research
advances as an important foundation for progress against P. vivax (18, 19).
Transmission of Plasmodium parasites depends upon the presence of male and
female gametocytes in blood ingested by feeding mosquitoes. P. vivax gametocytes
mature much more rapidly than those of P. falciparum and can be observed in the
bloodstream 3 to 5 days after the ﬁrst microscopic detection of asexually replicating
parasites, a ﬁnding that helps to explain why transmission can happen before or at the
ﬁrst development of vivax malaria symptoms (3, 9, 10, 20, 21). While fundamental
features of P. vivax and P. falciparum transmission biology are likely shared, P. falci-
parum gametocytes have conspicuously distinct morphologies, require 8 to 10 days to
mature, and accumulate/sequester during their development in the bone marrow
parenchyma before emergence into the blood circulation (22, 23). P. vivax invades
reticulocytes that are prevalent in the bone marrow parenchyma (24), and proportion-
ally increased distributions of gametocytes and young parasite stages have been
detected in the marrow aspirates of a clinical case (25). Together, these observations
suggest a role for the bone marrow in P. vivax infection. Here, we present a systematic
investigation of P. vivax tissue distributions and provide further evidence for enrich-
ment of transmission and replicative stages in the bone marrow and liver, relative to
peripheral blood.
RESULTS
Shared patterns of transcription in the development of P. vivax and P. falci-
parum gametocytes. P. vivax orthologs of conserved P. falciparum gametocyte and
gamete antigens (and transmission-blocking vaccine candidates), e.g., Pvs25, Pvs28,
Pvs48/45, and Pvs230, provide markers that can complement morphological observa-
tions and likewise have diagnostic and vaccine potential (26–28). To characterize the
expression proﬁles of P. vivax gametocytes and search further for stage-speciﬁc mark-
ers, we analyzed and compared the transcriptomes of P. vivax and P. falciparum
gametocytes over the course of their development to maturity.
Our previous work provided a comprehensive analysis of temporal relationships
among P. falciparum gametocyte transcripts, including the transcripts of 591 genes that
grouped into 29 clusters (established by 5 coexpressed genes), from the onset of
gametocytogenesis to ﬁnal maturation (29). These previous results identiﬁed (i) 5
transcript clusters from gametocyte ring (GR) stages during the ﬁrst day of develop-
ment, (ii) 15 transcript clusters from immature gametocyte (IG) stages during days 2 to
6 of development, and (iii) 9 transcript clusters from P. falciparum mature gametocytes
(MG) in their ﬁnal 2 days of development and maturation. To develop a corresponding
analysis of P. vivax transcript patterns, we identiﬁed a subset of P. falciparum
gametocyte-expressed genes having syntenic orthologs in P. vivax. Of this subset’s 591
P. falciparum genes in 29 clusters, 527 showed evidence of a syntenic ortholog in
P. vivax, whereas 64 did not have any clear ortholog and were therefore classiﬁed as
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missing from P. vivax (see Table S1 in the supplemental material). Among the P. falci-
parum gametocyte transcripts missing from P. vivax, many encode known P. falciparum
gametocyte-exported proteins (GEXP) (30).
In concert with comparative analysis of gametocyte transcripts, we analyzed the
orthologs of P. falciparum genes previously shown to be expressed in P. vivax asexual
blood stages (31). In experiments with three patient isolates, results from 9- to 57-h
periods of ex vivo P. vivax culture revealed cascades of coexpressed genes in similar
patterns (Fig. S1A) (both P. falciparum and P. vivax have 48-h asexual stage cycles).
Consistent with previous ﬁndings (31), transcripts from ring stages were readily de-
tected at the 51- and 57-h time points, indicating successful reinvasion of merozoites
after an initial cycle of asexual parasite development. Using the P. vivax orthologs of
P. falciparum gametocyte-expressed genes (Table S1), we analyzed the data for expres-
sion clusters of P. vivax sexual stages on the 9- to 57-h timeline. Progression through
GR, IG, and MG clusters was evident, with strongest signals from the MG clusters at the
57-h time point (Fig. 1A and B). This time to the appearance of MG clusters in P. vivax
ex vivo samples is consistent with microscopic observations of gametocyte develop-
ment within 3 days (32) and contrasts with the much longer periods reported for the
development of mature P. falciparum gametocytes (5 to 7 days for evidence of MG
transcripts from in vivo samples; 13 days or more for P. falciparum MG to be infectious
to mosquitoes) (29, 33). Interestingly, a subset of putative IG clusters in P. vivax was not
observed until the 51- to 57-h ex vivo time points and therefore was grouped with the
MG clusters. Taken together, these data support the presence of evolutionarily con-
served cascades of transcriptional clusters in P. vivax and P. falciparum gametocyte
development, although these two Plasmodium species exhibit very different maturity
times and morphologies of their gametocytes.
Relative underrepresentation of P. vivax immature gametocyte and late asexual
stages in patient blood. Our previous study showed that the stage-speciﬁc accumulation/
sequestration of P. falciparum parasites could be inferred from the transcription proﬁles of
blood samples (29). To develop a corresponding analysis of P. vivax stages, we examined
the transcription data from a previously published investigation of samples from eight
P. vivax-infected patients (34). Orthologs of the gametocyte- and asexual-speciﬁc tran-
scripts were assigned to P. vivax clusters as described above and grouped as deﬁned for
the P. falciparum study (29). In analysis of the sexual-stage clusters, we found that
transcription levels in the IG clusters were lower than in GR clusters (paired t test P 
0.0028) or MG clusters (paired t test P  0.0025) (Fig. 1C). Comparison of transcript
levels in the asexual clusters revealed a signiﬁcant underrepresentation of signal from
late asexual (22 h postinvasion [hpi]) relative to early asexual stages of P. vivax
(22 hpi) (paired t test P  0.0015) (Fig. 1C). This ﬁnding from the asexual stages is
consistent with conclusions that ring-stage parasites are present at greater prevalence
than trophozoites and schizonts in the blood of P. vivax-infected patients, and these
more mature stages of P. vivax accumulate/sequester (35, 36). Further, results from our
transcriptome-cluster analysis of GR, IG, and MG provided quantitative evidence for
differential representation of IG stages in circulating blood, which may be attributed to
their accumulation/sequestration in other tissues.
Selection of stage-speciﬁc markers and validation by quantitative real-time
PCR. Stage-speciﬁc quantitative real-time PCR (qRT-PCR) markers to investigate tissue
accumulation/sequestration were tested and validated with blood samples from Aotus
lemurinus lemurinus monkeys (37, 38) infected with P. vivax strain AMRU-I or SAL-I (39,
40) (Fig. S2 and S3; Table S2). Markers for this purpose were required to (i) be speciﬁc
for P. vivax gametocyte or asexual stages, (ii) have orthology to a P. falciparum marker,
and (iii) span an intron splice site, to avoid artifacts from spurious ampliﬁcations of a
genomic DNA (gDNA) template (Fig. S1B). In an approach analogous to our previous
identiﬁcation of P. falciparum stage-speciﬁc markers for use in multiplexed qRT-PCRs
(41, 42), we used ex vivo and in vivo transcript data plus available proteomics informa-
tion (http://www.PlasmoDB.org) to develop a short list of 16 P. vivax candidates
(Table S3). We also included PVX18s rRNA as a highly expressed constitutive transcript
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FIG 1 Stage-speciﬁc P. vivax gene expression ex vivo and in patients. (A) P. vivax gametocyte transcriptional dynamics ex vivo. P. vivax ex vivo transcriptome
data from three patient isolates (31) were reanalyzed for gametocyte transcriptional dynamics. In the heat map, P. vivax orthologs from P. falciparum
gametocyte genes were sorted along the developmental cycle according to stage speciﬁcity of previously deﬁned clusters of P. falciparum coexpression
(Continued on next page)
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for qRT-PCR assay normalization and the Pvs25 sequence as a reference standard for
detection of mature gametocytes (27, 28). Optimization of the exon-spanning primer
sets was performed using synthetic DNAs representing the expected cDNAs from each
mature mRNA sequence lacking the intron. We tested for ampliﬁcation efﬁciency in
dilution series of these synthetic cDNA templates, and 10 primer pairs showed PCR
ampliﬁcation efﬁciency of 90% (Table S3). We trimmed the candidate list further by
conﬁrming there was no spurious ampliﬁcation from the P. vivax gDNA template. The
above selection criteria were met by primer sets for two candidates: (i) PVX_117730,
encoding putative protein phosphatase PvPPM3, and (ii) PVX_117900, encoding the
P. vivax gamete surface antigen PvLAP5 (43), an ortholog of PfFNPA (PF3D7_1451600;
PF14_0491) in P. falciparum (44). The Pvs25 and PVX18s rRNA primer pairs were also
checked for efﬁcient product ampliﬁcation, but with P. vivax gDNA, as these genes lack
introns and were shown not to yield products with cDNA or gDNA from uninfected
Aotus NHP or humans. Identities of the PVX_117730, PVX_117900, Pvs25, and PVX18s
rRNA amplicons were veriﬁed by agarose gel electrophoresis and Sanger sequencing
(Fig. S4).
Next, qRT-PCR was used to test P. vivax-infected Aotus samples and ex vivo cultures
for signals from our candidate markers. In multivariate Spearman tests, PvPPM3 and
PvLAP5 transcript levels across Aotus samples and ex vivo cultures were both more
highly correlated with Pvs25 and each other than with PVX18s rRNA (Table 1), in
agreement with their gametocyte-speciﬁc patterns in ex vivo microarrays (Fig. 1). In an
AMRU-I-infected Aotus monkey (Fig. 2A), PvPPM3, Pvs25, and PvLAP5 transcripts in-
creased with parasitemia as well as PVX18s rRNA levels, consistent with previous reports
that P. vivax gametocytemia tracks with parasitemia (3, 21). These transcription proﬁles
of Pvs25 and the two new gametocyte markers were also in agreement with the
observed correlations of their expression (Table 1). After 48 h in ex vivo culture,
transcripts from PvPPM3, PvLAP5, and Pvs25 were detectable at levels similar to those
in blood directly drawn from infected Aotus NHP (Fig. 2B). We did not evaluate
additional markers due to the limited material obtained from the Aotus infections.
Validation of PvLAP5 gametocyte markers via immune ﬂuorescence assays.
There is a need for antibodies that can detect marker proteins speciﬁc to P. vivax
gametocytes. We therefore focused on antibodies against PvLAP5, as there is evidence
for expression of its P. falciparum ortholog, PfFNPA, during gametocyte development
(44, 45), and the transcription levels of PvLAP5 and Pvs25 are well correlated (Fig. 2A;
Table 1). For these experiments, we generated rabbit antibodies against PvLAP5
peptides and tested their signals with 48-h ex vivo samples from Aotus and from human
FIG 1 Legend (Continued)
analysis (29) (see Materials and Methods). The progression of transcript orthologs through the stages of P. vivax and P. falciparum gametocyte development
was similar, although the period of the immature gametocyte cycle was greatly extended in P. falciparum compared to P. vivax. (B) Three selected
transcriptional clusters including P. vivax markers PvPPM3 (cluster 240), PvLAP5 (cluster 241), and Pvg377 and Pvs25 (both cluster 49). (C) P. vivax gene
expression in patient samples. P. vivax transcriptome data from 8 patient isolates (CM12, CM13, CM101, CM106, CM108, CM114, CM115, and CMM08) (34)
were reanalyzed to deﬁne gametocyte transcript abundance in patient peripheral blood. (Left) Box plot showing mean expression across all genes
representing one of ﬁve categories: A. circ, asexual 0 to 22 hpi; A. seq., 22 to 48 hpi (gametocyte GR, IG, and MG). ***, P  0.005, paired t test. (Right) Heat
map showing mean expression per cluster (sorted as for panel A) for GR, IG, and MG stages. (Bottom) Heat map showing mean expression of young
circulating asexual stages and more mature asexual stages which accumulate/sequester in tissues. Dashed lines demarcate categories deﬁned previously for
P. falciparum (29).
TABLE 1 Transcript correlations based on qRT-PCR analysis
Gene
Strength of correlation between gene and transcripta
PvLAP5 PVX_117730 Pvs25 PVX18s rRNA
PvLAP5 1 0.9042*** 0.9738*** 0.8024***
PVX_117730 1 0.9108*** 0.8704***
Pvs25 1 0.8475***
PVX18s rRNA 1
aData are the P values for each comparison (***, P  0.0001). Data include all samples (n  13) collected
from Aotus blood and ex vivo time points.
Plasmodium vivax Infection in Bone Marrow ®
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FIG 2 Validation of stage-speciﬁc P. vivax markers. (A) P. vivax infection dynamics in Aotus. Samples were collected every 3 to 5 days starting at
peak parasitemia and analyzed by qRT-PCR and microscopy. qRT-PCR data were normalized to RNA input and presented as transformed cycle
threshold (CT) values. (B) qRT-PCR quantiﬁcation of candidate markers in the peripheral blood and corresponding 48-h ex vivo samples from Aotus
monkeys infected with P. vivax AMRU-I or SAL-I strains (n  3). Candidate markers and Pvs25 were quantiﬁed by qRT-PCR, and values were
normalized using PVX18s rRNA. Data are presented as transformed CT values. (C) Validation of marker antibodies by Western blotting using
(Continued on next page)
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patient isolates (from Brazil). Immunoblot assays of ex vivo Aotus samples and unin-
fected controls with these antibodies demonstrated a band of the expected size
(98.2 kDa) for PvLAP5 in infected blood samples (Fig. 2C). We also generated a speciﬁc
antibody against the P. vivax apical membrane protein 1 (PvAMA1), the functional
ortholog of the P. falciparum schizont marker and invasion determinant PfAMA1 (46)
(Fig. 2C), and we employed a monoclonal antibody against parasite lactate dehydro-
genase (pLDH) that detects both P. vivax and P. falciparum (47). After optimization for
the immunoﬂuorescence assay (IFA) signal, we veriﬁed speciﬁcity of the PvLAP5 and
PvAMA1 antibodies on methanol-ﬁxed ex vivo samples from Aotus and human infec-
tions. Parallel IFAs of infected red blood cells (iRBCs) ex vivo demonstrated that PvLAP5
stained a subset of singly nucleated parasites at the same rate as cells with morpho-
logical features of gametocytes, based on Giemsa smear (Fig. 2D and E).
P. vivax loads and stage distributions in blood, bone marrow, liver, and lung.
Considering the relative differences in stage-speciﬁc P. vivax transcripts in the human
circulation (Fig. 1C), we designed experiments to directly test if P. vivax parasites might
accumulate/be sequestered in vascular or extravascular niches. In a series of infections
(Table S4), Aotus and Saimiri tissue samples were collected in 13 autopsies from bone
marrow, lung, brain, liver, intestine, and subcutaneous fat. Histological analyses (Fig. 3)
and qRT-PCR (Fig. S4) were performed similarly to those in our investigation of
P. falciparum in human autopsy tissues (22), using the stage-speciﬁc markers developed
in this study. Antibodies against pLDH (all parasite stages), PvAMA1 (schizonts), and
PvLAP5 (gametocytes) detected parasites in the Aotus bone marrow, liver, and lung,
while few or no parasites were detected in the brain, intestine, or subcutaneous fat
(Fig. 3A and B; Table S5). Extrapolation of blood and tissue burden per animal indicated
that the largest total number of parasites was present in blood circulation, while bone
marrow and liver represented major tissue reservoirs for gametocytes and schizonts
(Fig. 3B). We analyzed blood smear counts and total blood volume per animal to
quantify the schizonts, gametocytes, and all-stage total parasites in the circulation of
each animal. Parasite counts in the tissues were estimated based on corresponding
counts of these forms in histological sections of deﬁned volumes, multiplied by the
estimated total tissue volume per animal (Fig. 3C). These calculations revealed average
per-animal loads of approximately 8  108 parasites in peripheral blood, 3  108
parasites in bone marrow, and 5  107 parasites in liver. Parasites in the bone marrow
and liver thus accounted for about 30% of the total parasite burden in these animals.
The data also showed that gametocytes and schizonts have enriched representation in
these tissues compared to peripheral blood: gametocytes account for more than 25%
of all parasites in the bone marrow and liver, compared to 10% in blood, and
schizonts account for 33% in the liver compared to 12% in the blood.
P. vivax accumulation/sequestration in bone marrow parenchyma and liver
sinusoids. Microscopic studies of the tissue specimens further demonstrated that the
vast majority of parasites in infected bone marrow and liver tissue were located outside
of the vasculature, in contrast to parasites in lung tissue, which were detectable only in
the vasculature (Fig. 4A; Table S5). Excluding parasites cleared by Kupffer cells, ex-
travascular parasites were observed in sinusoids but not in the hematopoietic region of
the parenchyma (Fig. 4B and C). In the bone marrow, the majority of parasites, including
schizonts and gametocytes, localized to the parenchyma, while only a small fraction
FIG 2 Legend (Continued)
Percoll-enriched blood samples from Aotus infected with P. vivax SAL-I. (Left) A single band was detected in the SAL-I Aotus lysate when we used
mouse monoclonal pLDH antibody at a 1:5,000 dilution (approximately 1  106 parasites/lane). (Middle) Rabbit anti-PvLAP5 peptide antibodies
(1:1,000 dilution) detected full-length protein at 98.2 kDa (arrow) in lysates from infected Aotus (lanes 1 and 3) and the P. falciparum ortholog at
100 kDa in lysate of the P. falciparum HB3 line (lane 4, approximately 1  106 parasites/lane from cultivated gametocytes). Lane 2, empty. (Right)
Lane 1, Aotus lysate; lane 2, P. falciparum HB3 lysate from schizont cultures. PvAMA1 peptide antibodies (1:1,000) detected a major band and
known AMA1 breakdown products in the P. falciparum HB3 schizont lysate but not in Aotus samples, presumably due to low yield (lane 1). (D)
Image of Giemsa-stained thin blood ﬁlm from Aotus ex vivo culture (44 h) showing a P. vivax gametocyte on the left and a vacuolated mature
form on the right (arrows). (E, left) IFA images obtained with PvLAP5 (top) and PvAMA1 antibodies (bottom). (Right) Gametocyte percentages
determined from PvLAP5 IFA-positive relative to total Giemsa-stained parasite counts in the ex vivo samples from three Brazilian P. vivax patients.
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was detected in sinusoids (Fig. 4D and E). In the bone marrow, the number of parasites
detected by pLDH was far greater than with PvLAP5 and PvAMA1, suggesting that the
majority of parasites were early stages not detected by either of these 2 antibodies.
Indeed, speciﬁc gametocyte staining with antibodies against the pan-gametocyte
FIG 3 P. vivax tissue accumulation/sequestration in nonhuman primates. (A) Representative images of parasites in the immunohistochemistry (IHC) analysis
of 4 tissues. pLDH, PvLAP5, and PvAMA1 antibodies were used to detect the parasite; CD31 antibodies stained the endothelium. Black arrowheads mark
parasites. (B) Quantiﬁcation of histological data. IHC analysis across 6 tissues from 13 monkeys was performed using parasite antibodies against pLDH, PvLAP5,
and PvAMA1. Highest counts for all three antibodies were detected in bone marrow, liver, and lung. Counts represent 500 high-power ﬁelds. Values are
expressed as means  standard errors of the means (SEM). (Bottom) Pie charts showing parasite distribution across tissues based on PvLAP5 (left) and PvAMA1
counts (right). Parasites in Kupffer cells (liver) were excluded from counts. BM, bone marrow. (C) Parasite and gametocyte burden in blood and tissues. Numbers
were calculated based on parasite counts from Giemsa-stained peripheral blood smears and from BM, liver, and lung tissues stained with antibodies for pLDH
(all parasites) or PvLAP5 (gametocytes). (Top) Total parasite load in each tissue. (Middle) Total gametocyte load in each tissue. (Bottom) Total schizont load in
each tissue. Parasites in Kupffer cells (liver) were excluded from thce ounts. Values are expressed as means  SEM.
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marker Pvs16 (48) marked about half of all pLDH cells in the bone marrow paren-
chyma. A similar observation was made when we stained infected red blood cells with
the P. falciparum ortholog Pfs16 in human bone marrow (22).
DISCUSSION
Observations of moderate numbers of mature as well as immature P. vivax stages in
the circulation have probably contributed to general misconceptions that P. vivax
malaria is benign, although evidence has repeatedly shown that this is a disease with
tremendous morbidity and mortality (4, 9, 49–51). Parasite accumulation/sequestration
in tissues is thought be an important contributor to the pathogenesis of severe vivax
malaria (49). Human case studies (25, 51, 52) have demonstrated P. vivax stages in
spleen, lung, and bone marrow, analogous to ﬁndings of accumulation/sequestration in
infections with other species of Plasmodium (53–57). P. vivax is also found in the deep
tissues of NHP (58, 59), and the presence of a signiﬁcant tissue reservoir of P. vivax and
related parasites, such as Plasmodium cynomolgi, has been predicted based on mea-
sured blood parasitemia compared to observed parasite growth dynamics in infections
of humans and animals (60).
In the present study, we used speciﬁc antibodies and quantitative histological
analysis to develop systematic analysis of P. vivax stage distributions in human blood
samples and major tissues of the Aotus and Saimiri NHP models. Comparative analysis
of transcriptional proﬁles from P. vivax ex vivo and P. falciparum in vitro time courses
FIG 4 P. vivax accumulation/sequestration in bone marrow and liver. (A) Intra- and extravascular parasite distributions across tissues. Quantiﬁcation of IHC data
across three tissues was based on CD31 staining to differentiate intravascular from extravascular parasite localization. Parasites in macrophages were excluded
from the analysis. Data demonstrated that most parasites are extravascular in the bone marrow and liver, but not in the lung. Data are from the tissues of 13
monkeys. m, macrophage. (B) Extravascular parasite distribution in liver. Quantiﬁcation of IHC data in liver sinusoids and parenchymas is shown. All parasites
counted were present in sinusoids. Data are from the tissues of 13 monkeys. (C) Representative image of infected liver tissue. Shown are parasites in Kupffer
cells (black arrowhead) and in sinusoids (yellow boundary). (D) IHC results showing extravascular parasite distribution in the bone marrow sinusoids and
parenchyma. The majority of parasites counted were in the parenchyma. In bone marrow, gametocytes but not schizonts were mostly extravascular. (Right)
Stage fraction in BM parenchyma (stacked bar with pLDH [taken as 100]). Schizonts were quantiﬁed based on PvAMA1-positive parasites, and gametocytes were
quantiﬁed based on Pvs16- or PvLAP5-positive parasites. The remainder (after subtracting PvAMA1 and Pvs16/PvLAP5 counts from pLDH counts) were
cataloged as the early-stage fraction. Data are from the tissues of 13 monkeys. (E) Representative images of infected bone marrow tissue. Extravascular parasites
are marked with white arrows; the image on the right shows two parasites associated with erythroblastic islands.
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indicates similar dynamics of asexual and sexual gene expression, even though the
development time for P. vivax gametocytes is much shorter than that for P. falciparum
gametocytes. These similarities demonstrate conservation of essential pathways of
development despite deep evolutionary divisions between the distinct species.
Our results indicate relatively lower counts of mature asexual and immature game-
tocytes in the circulating blood of P. vivax patients. These ﬁndings are consistent with
PvAMA1 and PvLAP5 staining results from the tissues of infected Aotus and Saimiri
monkeys. The histological data demonstrate a major fraction of gametocytes in the
parenchyma of the bone marrow, whereas asexual schizont forms are enriched to a
somewhat lesser extent in this region of the bone marrow as well as in sinusoids of the
liver. Smaller fractions of gametocytes and schizonts are represented in the blood
circulation. These ﬁndings corroborate the hypothesis that subpopulations of asexual
and gametocyte stages accumulate/sequester from the circulating blood during
P. vivax infection, similar to our previous observations with P. falciparum. Use of
additional stage-speciﬁc markers and accumulation/sequestration studies in spleen-
intact NHP as well as human autopsies will be needed for further information on the
importance of these stage distributions for P. vivax transmission and pathogenesis.
Although recent data suggest that rosetting may contribute to P. vivax vascular
accumulation/sequestration (61, 62), the host-parasite interactions underlying the dis-
tribution patterns observed in our study are unknown. A signiﬁcant fraction of parasites
in the bone marrow parenchyma (40%) are young stages (positive for pLDH but
negative for PvLAP5, Pvs16, and PvAMA1), conﬁrming detection of signiﬁcant levels of
ring-stage parasites in bone marrow aspirates (25). P. vivax invades young reticulocytes
that are prevalent in the bone marrow parenchyma (24), so that early stages of P. vivax
development may have a preference for this hematopoietic environment (63). This
scenario may have implications for efforts to establish P. vivax culture in vitro, as bone
marrow reticulocytes are phenotypically different from the more mature forms present
in the blood circulation (64). Localization of the parasites to a reservoir in the bone
marrow may help to explain why many P. vivax infections in Africa have gone unde-
tected (5), and it also raises the possibility that recurrent blood-stage parasitemias can
arise from bone marrow as well as from relapses of hypnozoite stages in the liver.
MATERIALS AND METHODS
P. vivax gene annotation through ortholog mapping.We mapped P. vivax transcripts by using the
stage and cluster annotations of P. falciparum (29) after identiﬁcation of their orthologs in PlasmoDB
(http://www.plasmodb.org). Only syntenic ortholog mappings were considered. For asexual annotation,
3,990 out of 4,396 asexual P. falciparum genes had P. vivax orthologs. Most variant genes were excluded
due to lack of syntenic orthologs. P. vivax genes were then labeled for cluster and stage according to
their P. falciparum gene ortholog; 244 out of 249 asexual clusters had at least one corresponding P. vivax
gene. Out of the 591gametocyte genes annotated as gametocyte speciﬁc in a previous report (29), 527
had corresponding P. vivax orthologs. All 29 gametocyte clusters had at least one P. vivax gene
representative, and 27 clusters had at least ﬁve genes. These annotations were used for stage-speciﬁc
P. vivax gene expression analysis.
Microarray data analysis. We obtained time course and cross-sectional microarray P. vivax expres-
sion proﬁles of infected blood samples from references 31 and 34, respectively. The expression values
from reference 31 were already ﬁltered, normalized, and transformed. Expression values from reference
34 were also normalized and only log-transformed and averaged across technical replicates. For
comparison of gene expression levels of different stages (Fig. 1C, box plots), expression levels were
averaged across all genes with the same stage annotation. P values were assigned based on two-sample
paired t tests. Similarly, gene expression levels were averaged clusterwise for comparison of different
clusters (Fig. 1C, heat maps).
Animals, infection protocol, and sample collection for bloodstream P. vivax analysis. (i)
Animals. Fourteen spleen-intact male and female laboratory-bred Aotus lemurinus lemurinus monkeys
karyotypes VIII and IX (65), with body weights between 758 and 829 g, were used as donors, experi-
mental subjects, or controls. The animals were housed at Gorgas Memorial Institute of Health Studies
(ICGES) in Panama and cared and maintained as described elsewhere (38). All animals received daily
veterinary care, which included regular physical examinations and body weight determinations at least
four times a year, deworming (mebendazol, Pantelmin; Janssen-Cilag, New Brunswick, NJ), as well as
vitamin B12 (Catosal; Bayer, Shawnee Mission, KS) and vitamins A, D, and E (Vigantol; Bayer) injections.
Rooms had climate control with 12 air changes per hour, min-max temperatures set to 70 to 76°F and
70 to 80% humidity, with a ﬂuorescent red/white light 12-h cycle starting at 03:00 p.m. A balanced
mixture of fruits and laboratory primate chow was provided to meet their caloric requirements. Water
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was administered daily in plastic bottles ﬁtted with a zip tube (Girton; Millville, PA). The animals were
kept in pairs in stainless steel 4-unit quad cages (Lab Products Inc., Seaford, DE) with dimensions of 27
by 23.5 by 29.5 inches. Each cage was ﬁtted with a 3/4-inch-diameter polyvinyl chloride (PVC) pipe perch
placed across 2/3 of the length of the cage and a 6-inch-diameter, 14.5-inch-long PVC T pipe nest box
attached to the roof and back of the cage with cable zip ties. Cages were routinely cleaned and sterilized
at 180°F at weekly intervals in a cage washing machine (Steris, Erie, PA). During experimental infections,
the animals did not receive analgesics, nor were they trained for special procedures. The experimental
protocol was approved by the Gorgas Memorial Institute of Health Studies, Institutional Laboratory
Animal Care and Use Committee (CIUCAL) in accordance with procedures described in the Guide for the
Care and Use of Laboratory Animals (76) (protocol approval number 2011/02). All experiments described
here were performed in accordance with the approved guidelines.
(ii) Infection protocol. A frozen parasite stabilate of P. vivax SAL-I or AMRU-I was thawed and
inoculated into the saphenous vein of experimental spleen-intact Aotusmonkeys as described previously
(66). Giemsa-stained thick blood smears were then examined daily from a prick in the marginal ear vein,
starting on day 5 postinoculation (p.i.), and parasitemia was evaluated and reported as the number of
parasites per microliter using the method described in 1932 by Earle and Perez (67).
(iii) Sample collection. For expansion of P. vivax parasite populations, we inoculated one donor
animal each with AMRU-I and SAL-I, respectively, and passaged the parasites in four experimental
animals once parasitemia reached 5  103/l (Table S2). Parasitemia was monitored, and the animals
were bled once for experimental samples (Fig. S2); when parasitemia reached a peak of 8.0  103
parasites per liter (between days 12 and 15 postinfection), 3.5 ml of blood was collected from the
femoral vein in sodium citrate anticoagulant and spun down, and the plasma was separated and frozen
for later use. The iRBC pellet was washed three times with phosphate-buffered saline (PBS; pH 7.2) and
further divided: one aliquot containing 500 l of packed RBCs was preserved in Glycerolyte and stored
in liquid nitrogen as a stock repository; the remaining 1.5 ml of packed RBCs was split into 4 aliquots for
subsequent use in qRT-PCR, Western blot analysis, IFA, and ex vivo culture. For qRT-PCR, packed RBCs
were resuspended in 2.5 ml of McCoy’s medium supplemented with 20% human serum and passed once
through a CF11 cellulose column previously stabilized with PBS (pH 7.2) to exclude white blood cells from
the sample (68). The recovered RBC eluate was further centrifuged, washed three more times in PBS, and
adjusted to a 20% hematocrit with McCoy’s medium to a suspension volume of ~1.3 ml. At this point,
blood was mixed with 5 parts of Trizol for mRNA preservation. For Western blot analysis, packed RBCs
were treated with saponin at 0.15% and centrifuged, and the pellet was washed, resuspended in SDS
sample buffer, and frozen until further use. For IFA, the RBC sample was diluted 1:1,000 in PBS, spotted
onto slides, ﬁxed with methanol, and frozen until used for either IFA or Giemsa staining. For ex vivo
culture, RBCs were overlaid onto a 45% Percoll cushion as described previously (69–71) and then
centrifuged, and the band containing enriched mature P. vivax-infected RBCs (trophozoites, schizonts,
and gametocytes) was collected and processed for Western blotting and IFA smears as described above.
The pellet containing mostly ring forms was washed in PBS, resuspended in 5 ml of McCoys’s complete
medium, and cultured in Corning Costar tissue culture 6-well plates (Sigma-Aldrich, St. Louis, MO) at 37°C
in a culture hermetic bubble in an atmosphere of 90% N2, 5% CO2, and 5% O2 for 48 to 96 h, replacing
the gas mixture every 24 h without changing the medium. Giemsa-stained smears were taken at 24 and
48 h, and at 48 h additional aliquots were collected for qRT-PCR and IFA experiments as described above.
Finally, the animals were rescued by treatment with meﬂoquine (MQ) at 20 mg/kg of body weight orally
once to end the experiment.
To measure the dynamics of infection and gametocytogenesis, we treated an animal with CQ. This
approach is based on the observation that gametocytogenesis is enhanced when subjects are treated
with CQ or pyrimethamine, as it has been demonstrated in the Plasmodium chabaudi rodent malaria
model (72–75). Speciﬁcally, we used the CQ-resistant P. vivax AMRU-I strain for this experiment, assuming
that CQ treatment would sufﬁciently stress the parasite population to increase gametocyte production
without clearing the asexual infection. We infected one Aotus monkey with P. vivax AMRU-I, and the
animal was then treated at peak parasitemia and at recrudescence with CQ at 15 mg/kg orally for 3 days.
During infection follow-up for the last 50 days p.i., blood samples were collected at 9 time points,
approximately 3 to 5 days apart, to measure dynamics of infection by qRT-PCR and Giemsa smear.
Nonhuman primate terminal studies. All NHP animal acquisition, transportation, housing, care,
procedures, and release from studies were performed according to the National Institutes of Health (NIH)
Animal Research Advisory Committee (NIH ARAC) guidelines, protocols approved by the National
Institute of Allergy and Infectious Diseases (NIAID) Animal Care and Use Committee (NIAID ACUC), and
in compliance with the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals (76).
Brieﬂy, Saimiri and Aotus monkeys were socially housed, consistent with the experimental design, in
accord with the NIAID DIR Animal Care and Use Program Policy on Social Housing of Nonhuman
Primates. All husbandry was consistent with the current state of the art for New World nonhuman
primate care, including maximum quiet, fully enclosed nesting areas, a 12-h light-dark cycle, and safe
toys. Daily cleaning and technician health checks were conducted as quietly and unobtrusively as
possible. Individual animal records were taken to reﬂect all procedures conducted. A balanced mixture
of fruits and laboratory primate chow were provided to meet their caloric requirements.
Only splenectomized animals that participated in multiple malaria studies and were eligible for ﬁnal
bleed were utilized for postmortem sample collection by NIH pathologists.
Approximately 103 to 105 P. vivax pRBCs from cryopreserved or fresh NHP blood were utilized to
infect animals intravenously (i.v.). Animals were monitored weekly or daily based on blood smears,
hematocrit, and weight. Animals in this study experienced only subclinical signs from the infection
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(namely, blood RBC parasitemia and minor hematocrit depression). Any monkey that reached a para-
sitemia of 5% or more or a hematocrit of 25% or less was immediately treated for cure of parasites,
including on weekends and holidays, with MQ (25 mg, single dose, orally) or Malarone (weight-adjusted
pediatric dose of 25 mg/kg/day atovaquone plus 10 mg/kg/day Proguanil, orally for 3 days). Criteria for
consideration of euthanasia (at the discretion of the attending veterinarian, after consultation with the
Principal Investigator) included the initial and current hematocrit, initial and current degree of para-
sitemia, other indicators of response to the antimalarial drug treatment, and the general health condition
of the animal. No animal suffered unnecessarily. Euthanasia was performed in accordance with the Guide
for the Care and Use of Laboratory Animals (76).
P. vivax ex vivo culture from human patient samples. Cryopreserved Brazilian P. vivax isolates
were obtained through the “Efﬁcacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and
Primaquine for P. vivax Infection” clinical trial (NCT02691910) with written informed consent from all
patients (Institutional Review Board of the Institute of Biomedical Sciences, University of São Paulo, Brazil
[1169/CEPSH, 2014]). Cryopreserved isolates were thawed as previously described (77). Subsequently,
P. vivax ring-stage parasites were enriched on a 1.080 g/ml KCl-Percoll gradient. Brieﬂy, 1.080 g/ml
KCl-Percoll was achieved by combining KCl high isotonic Percoll (10 mM HEPES, 115 mM KCl, 12 mM
NaCl, ﬁnal) at 35.97% with the KCl high buffer at 64.03%, as described by Roobsoong et al. (78). Density
was conﬁrmed with a DMA 35 portable density meter (Anton Paar; Graz, Austria). Density gradients were
assembled by layering one part thawed cells in incomplete Iscove’s modiﬁed Dulbecco’s medium (IMDM)
(3 to 50% hematocrit) on one part density gradient and then centrifuged for 15 min at 1,200  g.
Enriched parasites were collected from the interface, washed twice with incomplete IMDM, and ﬁnally
resuspended at 1 to 2% hematocrit in completed IMDM (10% heat-inactivated pooled AB human sera
from Interstate Blood Bank, Inc. [Memphis, TN] and 50 mg/ml gentamicin) and moved into culture.
Cultures were maintained at 37°C in 5% CO2, 1% O2, and N2 to balance. Parasitemia and asexual and
gametocyte maturation were assessed by either light microscopy analysis or methanol-ﬁxed and
Hemacolor-stained cytospins (Shandon Southern Instruments, Sewickley, PA).
Sample processing and RNA extraction. For blood samples (Aotus, ex vivo samples), RNA was
extracted from Trizol samples by using a Qiagen RNeasy Plus kit including a gDNA eliminator column
(Qiagen, Valencia, CA), according to the manufacturer’s protocols.
Tissue samples from monkeys were either fresh frozen or stored in RNAlater (Qiagen) for subsequent
RNA analyses. All tissues were completely homogenized in RLT lysis buffer (Qiagen) and using a Polytron
homogenizer (Kinematica). Homogenized tissue lysate was centrifuged at 15,000 rpm for 15 min to
remove undigested material (pellet), and the resulting clear supernatant was subsequently used for RNA
extraction using an RNeasy plus minikit (Qiagen). The lysate was passed through gDNA eliminator
columns (Qiagen) to remove genomic DNA, and RNA was extracted according to the manufacturer’s
protocol. RNA was eluted in nuclease-free water. An additional gDNA removal step was performed using
Turbo DNase (Ambion) treatment for subsequent qRT-PCR analyses. RNA concentrations were measured
in a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientiﬁc, Cambridge, MA),and samples were
stored 80°C until cDNA synthesis.
cDNA synthesis. Reverse transcription was performed with an Invitrogen SuperScript III ﬁrst-strand
system for RT-PCR (Life Technologies, Inc., Carlsbad, CA). Brieﬂy, 8 l containing ~1 pg to 5 g of total
RNA was extracted by the Trizol method described above and used as the template in a 20-l volume.
After the reaction was stopped, RNase H was added for 20 min and then the samples were stored at
20°C until use. One extra reaction mixture without reverse transcriptase (RT-) was carried out as a
negative control for genomic DNA contamination in all samples.
Primers for the qRT-PCR assay. To quantify stage-speciﬁc gene expression of selected P. vivax
markers by qRT-PCR, we designed forward and reverse primers by using the following criteria: (i)
maximum size of 20 bp; (ii) GC content of 55%; (iii) melting temperature (Tm) of 60°C; (iv) PCR product
length of 70 to 200 bp. In addition, primers for the candidate gametocyte markers and the constitutive
marker PVX_091645 were designed such that one of the two primers spanned an exon-exon junction, in
order to minimize ampliﬁcation from gDNA. Primers were synthesized by GenScript (Piscataway, NJ) and
optimized on synthetic cDNA templates as described in Results and for Fig. 2A. For standard controls, we
used Pvs25 (PVX_111175) and Pv18s rRNA.
PCR ampliﬁcation was performed in 20-l volumes with a Fast SYBR Green qPCR master mix system
from Life Technologies, Inc., and an Applied Biosystems ViiA 7 real-time qPCR thermocycler system.
Generation of peptide antibodies against PvLAP5 and PvAMA1. Peptides used for rabbit immu-
nizations are listed in Table S3. Antisera were generated by immunization of one rabbit per construct
using standard protocols (GenScript, Piscataway, NJ). Preimmune serum samples were harvested for each
study animal on the day prior to immunization (day 1) to immunization. On day zero, each animal was
immunized by intraperitoneal injection (i.p.) with a primary dose of 50 g of recombinant protein in
Freund’s complete adjuvant. This was followed by three boosts of 25 g protein in Freund’s incomplete
adjuvant administered i.p. on days 14, 25, and 56. Antisera were collected on day 63 and tested in an
enzyme-linked immunosorbent assay for reactivity against the recombinant protein relative to preim-
mune control serum samples.
Western blot analysis. For immunoblot analysis, 375 l of peripheral blood at a peak parasitemia
of ~8.0  103 parasites/l was collected from Aotus monkeys infected with P. vivax SAL-I; the blood
samples were treated with 0.1% saponin in 1 PBS buffer to release parasites. Saponin-lysed parasites
(3.0  106) were resuspended in 10 volumes (15 l) of SDS lysis buffer, and 5 l (1.0  106) of each
sample was used for Western blotting. Blood from an uninfected Aotus monkey was used as a negative
control. Mouse anti-pLDH antibodies at a 1:5,000 dilution, rabbit anti-PvLAP5 antibodies (GenScript) at a
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1:1,000 dilution, and rabbit anti-PvAMA1 antibodies (GenScript) at a 1:1,000 dilution were used. Horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgG (HL) and goat anti-rabbit IgG (HL) second-
ary antibodies were used for detection.
Immunoﬂuorescence assays. P. vivax AMRU-I and SAL-I samples from each inoculated Aotus animal
were collected for thick and thin blood smear examination by Giemsa staining and bright-ﬁeld micros-
copy. Aotus blood and ex vivo samples were spotted onto 10-well slides, ﬁxed in methanol, and
snap-frozen until further use. For IFA, slides were thawed and processed for staining. For antibody
optimization, slides were incubated in a humid chamber for 1 h with serial dilutions of 1:500 to 1:5,000
antibody titers in bovine serum albumin-PBS (pH 7.2) buffer and then washed thoroughly with PBS 3
times. Samples were further labeled with secondary goat anti-rabbit Alexa Fluor 488-ﬂuorescein isothio-
cyanate–conjugated antibodies (Invitrogen Molecular Probes, Eugene, OR), diluted 1:500, and incubated
for 30 min. After a ﬁnal wash with PBS, samples were mounted and counterstained with Vectashield
4=,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA) and analyzed with a Nikon Eclipse
TE300 inverted ﬂuorescence microscope.
Histological assays. Formalin-ﬁxed tissues from monkeys were embedded in parafﬁn blocks, and
sections of 5-m thickness were obtained for each tissue. For immunohistochemistry analysis, sections
were processed through deparafﬁnization steps in xylene followed by dehydration steps through a
graded ethanol series (100% to 50%). Antigen retrieval was performed by incubating slides at 95°C in a
steamer for 30 min and using a universal antigen retrieval reagent (R&D Systems). Following antigen
retrieval, blocking was performed using Tris-buffered saline blocking buffer (Thermo Scientiﬁc) for
20 min, followed by 10 min each with avidin and biotin blocking buffers (Invitrogen) to block endog-
enous biotin and avidin, respectively. Double labeling of parasite-speciﬁc antigens (pLDH, PvLAP5,
PvAMA1, and Pvs16) and blood vessels (CD31) was performed by the following protocol of antibody
dilutions and incubations. Mouse monoclonal anti-pLDH antibodies were used at 1:1,000 dilution in
combination with rabbit anti-CD31 antibodies (Abcam, Inc.) at 1:20 dilution. Rabbit anti-PvLAP5 anti-
bodies (1:500), rabbit anti-PvAMA1 antibodies (1:500), or rat anti-Pvs16 antibodies (1:500) were each used
in combination (1:20) with mouse anti-CD31 antibodies (Abcam, Inc.). Primary antibodies were diluted in
blocking buffer and incubated overnight at 4°C. Secondary antibodies were selected to label parasites in
red and blood vessels in brown. HRP-conjugated goat anti-rabbit or anti-rat–HRP antibodies and a biotin
conjugate of the F(ab’)2 fragment of goat anti-mouse IgG (HL) antibodies were used (Invitrogen)
(diluted to 1:500 in universal blocking buffer), followed by streptavidin conjugated to alkaline phospha-
tase (AP; Thermo Scientiﬁc) (diluted 1:3,000 in universal blocking buffer). For the development of signal,
3,3=-diaminobenzidine (DAB) chromogen reagent (Thermo Scientiﬁc) was added for 20 min for devel-
opment of brown color. The slides were washed in water, and Fast Red 4 TR/naphthol AS-MX substrate
reagent (Sigma-Aldrich) was applied for 5 min. Slides were subsequently rinsed in water and counter-
stained in Mayer’s hematoxylin and mounted in aqueous mounting medium. Images of the slides were
captured using a whole-slide imaging system, and parasites were quantiﬁed by counting 500 consecutive
high-power ﬁelds at 400 magniﬁcation. Intravascular and extravascular parasite localization was
quantiﬁed with respect to CD31-positive blood vessels.
Calculation of tissue and blood parasite burdens. (i) Bone marrow. For calculation of parasite
burdens, ﬁrst the volume of the bone marrow from each animal was calculated using total body weight
and the assumption it represented 4% of body weight and had a density of 1.03 g/cm3 (79). Second the
volume of the slide measurement (500 high-power ﬁelds [hpf]) was calculated as follows: length
(160 m)  width (160 m)  section depth (5 m), i.e., 3.2  106 cm3. The volume of bone marrow
was then divided by the volume of the slide to give the number of bone marrow units per animal. The
resulting number was multiplied by the number of parasites per 500 hpf to give the total number of
parasites in bone marrow for each animal.
(ii) Liver. For liver burdens, the volume of the liver was calculated using total body weight and an
assumption it represented 27 ml per kg (79). The volume of the liver was then divided by the volume of
the slide (see above, 3.2  106 cm3) to give the number of liver units per animal. The resulting number
was multiplied by the number of parasites per 500 hpf to give the total number of parasites in liver for
each animal.
(iii) Lung. For lung burdens, the volume of the lung was calculated using total body weight and an
assumption it represented 7.7 ml per kg (79). The volume of the lung was then divided by the volume
of the slide (see above, 3.2  106 cm3) to give the number of lung units per animal. The resulting
number was multiplied by the number of parasites per 500 hpf to give the total number of parasites in
lungs for each animal.
(iv) Peripheral blood. For peripheral blood parasite burdens, the total volume of blood was
calculated using total body weight and an assumption it represented 50 ml per kg (79); based on that
volume, the total RBC count was calculated using an estimate of 5  106 red cells/l. This number was
multiplied by the measured parasitemia to give the total number of parasites in peripheral blood for each
animal.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00625-18.
FIG S1, TIF ﬁle, 4.9 MB.
FIG S2, TIF ﬁle, 4.5 MB.
FIG S3, TIF ﬁle, 32.7 MB.
Plasmodium vivax Infection in Bone Marrow ®
May/June 2018 Volume 9 Issue 3 e00625-18 mbio.asm.org 13
 
m
bio.asm
.org
 o
n
 M
ay 11, 2018 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
FIG S4, TIF ﬁle, 7.1 MB.
TABLE S1, XLSX ﬁle, 0.2 MB.
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